Source: Myeloma – Hematology Advisor
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Read More
by | Nov 17, 2022 | Myeloma News | 0 comments
Source: Myeloma – Hematology Advisor
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Read More